Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein

Our objective was to quantitate the contribution of the genetic polymorphism of the human MDR1 gene to the bioavailability and interaction profiles of digoxin, a substrate of P‐glycoprotein.

[1]  M. Fromm,et al.  The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.

[2]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Nawarskas,et al.  Digoxin Toxicity Secondary to Clarithromycin Therapy , 1997, The Annals of pharmacotherapy.

[4]  Y. Tanigawara,et al.  Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. , 1993, The Journal of pharmacology and experimental therapeutics.

[5]  S. Higuchi,et al.  Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects , 1996 .

[6]  T. Tsuruo,et al.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. , 1988, Cancer research.

[7]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[8]  J. Beijnen,et al.  The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[9]  K Ueda,et al.  P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. , 1989, Biochemical and biophysical research communications.

[10]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Laurence,et al.  Clinical Pharmacology & Therapeutics , 1980, Palgrave Macmillan UK.

[12]  M. Abecassis,et al.  Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. , 1999, Transplantation.

[13]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[14]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Y. Tanigawara,et al.  Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. , 1993, The Journal of pharmacology and experimental therapeutics.

[16]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[17]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Yim,et al.  Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[19]  D. Meijer,et al.  Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted , 1998, British journal of pharmacology.

[20]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[21]  O. Etingin,et al.  Clarithromycin-related toxic effects of digoxin. , 1995, The New England journal of medicine.

[22]  I. D. de Lannoy,et al.  The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. , 1992, Biochemical and biophysical research communications.

[23]  G. Koren,et al.  P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. , 1993, Life sciences.

[24]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  D. Meijer,et al.  Contribution of the murine mdr1a P‐glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption , 1998, Hepatology.

[26]  T. Furukawa,et al.  Function of P-glycoprotein expressed in placenta and mole. , 1997, Biochemical and biophysical research communications.

[27]  S. Higuchi,et al.  Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. , 2001, Pharmacogenetics.

[28]  G R Wilkinson,et al.  Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.

[29]  L. Benet,et al.  The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine , 1995, Clinical pharmacology and therapeutics.

[30]  J. Beijnen,et al.  Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. , 1996, Journal of the National Cancer Institute.

[31]  G. Koren,et al.  Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1). , 1993, Canadian Journal of Physiology and Pharmacology.

[32]  G Koren,et al.  Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. , 1998, Veterinary and human toxicology.

[33]  J. Kigawa,et al.  Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.

[34]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[35]  Clarithromycin-associated digoxin toxicity in the elderly. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[37]  G. Koren,et al.  Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. , 1992, The American journal of physiology.

[38]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[39]  P. Lundborg,et al.  Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole , 1990, Clinical pharmacology and therapeutics.

[40]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Baas,et al.  Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. , 1993, Pharmacology & therapeutics.

[42]  T. Futami,et al.  Effect of clarithromycin on renal excretion of digoxin: Interaction with P‐glycoprotein , 1998, Clinical pharmacology and therapeutics.

[43]  R. Oertel,et al.  Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil , 1999, Clinical pharmacology and therapeutics.

[44]  M Zschiesche,et al.  Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein , 2000, Clinical pharmacology and therapeutics.

[45]  Piet Borst,et al.  Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein , 1996, British journal of pharmacology.

[46]  V. Armstrong,et al.  No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. , 2001, Clinical chemistry.

[47]  H. McLeod,et al.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. , 2001, Pharmacogenetics.

[48]  Y. Tanigawara,et al.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). , 1992, The Journal of pharmacology and experimental therapeutics.

[49]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.

[50]  L. Benet,et al.  Tacrolimus oral bioavailability doubles with coadministration of ketoconazole , 1997, Clinical pharmacology and therapeutics.